EA201992826A1 - 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ - Google Patents

15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ

Info

Publication number
EA201992826A1
EA201992826A1 EA201992826A EA201992826A EA201992826A1 EA 201992826 A1 EA201992826 A1 EA 201992826A1 EA 201992826 A EA201992826 A EA 201992826A EA 201992826 A EA201992826 A EA 201992826A EA 201992826 A1 EA201992826 A1 EA 201992826A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibition
hydroxysteroiddehydrogenases
15beta
17beta
propanamido
Prior art date
Application number
EA201992826A
Other languages
English (en)
Inventor
Лена Хирвеля
Марьо Хакола
Теро Линнанен
Паси Коскимиес
Камилла Штьерншанц
Original Assignee
Форендо Фарма Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Форендо Фарма Лтд filed Critical Форендо Фарма Лтд
Publication of EA201992826A1 publication Critical patent/EA201992826A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к соединениям формулы (I) и их фармацевтически приемлемым солям, где R1-R4 являются такими, как определено в формуле изобретения. Изобретение также относится к их применению в качестве ингибиторов 17-HSD1 (17-гидроксистероиддегидрогеназа 1 типа) и в лечении или предупреждении зависимых от стероидных гормонов заболеваний или расстройств, таких как зависимые от стероидных гормонов заболевания или расстройства, при которых необходимо ингибирование фермента 17-HSD1 и/или при которых необходимо уменьшение концентрации эндогенного эстрадиола. Настоящее изобретение также относится к получению вышеупомянутых соединений и к фармацевтическим композициям, содержащим в качестве активного(ых) ингредиента(ов) одно или более из вышеупомянутых соединений или их фармацевтически приемлемых солей.
EA201992826A 2017-06-08 2018-06-07 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ EA201992826A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20175530 2017-06-08
PCT/FI2018/050427 WO2018224736A2 (en) 2017-06-08 2018-06-07 Therapeutically active steroidal derivatives

Publications (1)

Publication Number Publication Date
EA201992826A1 true EA201992826A1 (ru) 2020-05-14

Family

ID=62716091

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992826A EA201992826A1 (ru) 2017-06-08 2018-06-07 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ

Country Status (19)

Country Link
US (3) US10717761B2 (ru)
EP (1) EP3634975B1 (ru)
JP (3) JP7064515B2 (ru)
KR (1) KR102420512B1 (ru)
CN (2) CN115716860A (ru)
AU (1) AU2018279205B2 (ru)
CA (1) CA3066196C (ru)
CL (1) CL2019003562A1 (ru)
DK (1) DK3634975T3 (ru)
EA (1) EA201992826A1 (ru)
FI (1) FI3634975T3 (ru)
IL (2) IL294140B1 (ru)
MX (2) MX2022000747A (ru)
NZ (1) NZ760155A (ru)
PT (1) PT3634975T (ru)
SG (1) SG11201911776PA (ru)
UA (1) UA126342C2 (ru)
WO (1) WO2018224736A2 (ru)
ZA (1) ZA201908404B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220041647A1 (en) * 2018-12-05 2022-02-10 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
CN114644673B (zh) * 2020-12-19 2023-12-26 上海喀露蓝科技有限公司 一种雌二醇衍生物、其制备方法及其在医药上的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323089A1 (en) 1998-03-11 1999-09-16 Endorecherche, Inc. Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
AR036492A1 (es) 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
MXPA04003611A (es) 2001-10-17 2004-07-30 Schering Corp Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
ES2345146T3 (es) 2002-11-18 2010-09-16 Schering Corporation Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
JP4585320B2 (ja) 2002-12-17 2010-11-24 シェーリング コーポレイション 男性ホルモン依存性疾患の処置のための１７β−ヒドロキシステロイドデヒドロゲナーゼ３型インヒビター
WO2004085345A2 (en) 2003-03-21 2004-10-07 Yale University 15α-SUBSTITUTED ESTRADIOL CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS
GB0306718D0 (en) 2003-03-24 2003-04-30 Sterix Ltd Compound
US20040224935A1 (en) 2003-04-07 2004-11-11 Endorecherche, Inc. Topical antiandrogenic steroids
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
TWI331154B (en) * 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
DE102004032673A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1
DE102004032674A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
US7575828B2 (en) 2004-07-23 2009-08-18 Kim Manufacturing Co. Modular rack assemblies for sealed lead acid batteries
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
RU2412196C2 (ru) 2005-05-26 2011-02-20 Зольвай Фармасьютиклз Гмбх ИНГИБИТОРЫ 17β-ГСД1 И СТС
US8030298B2 (en) * 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
RU2469042C2 (ru) 2006-09-19 2012-12-10 Зольвай Фармасьютиклз Гмбх Терапевтически активные триазолы и их использование
EP2099814A1 (en) 2006-11-30 2009-09-16 Solvay Pharmaceuticals GmbH Substituted estratrien derivatives as 17beta hsd inhibitors
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
EP2376408A4 (en) 2008-11-20 2012-06-20 Harvard College FLUORATION OF ORGANIC COMPOUNDS
CA2830984C (en) 2011-03-25 2020-02-11 Universite Laval Inhibitors of 17.beta.-hsd1, 17.beta.-hsd3 and 17.beta.-hsd10.
CN105518015B (zh) * 2013-06-25 2017-09-15 佛恩多制药有限公司 治疗活性的作为17β‑羟基类固醇脱氢酶抑制剂的17‑氮取代雌三烯噻唑衍生物
CN105518016B (zh) * 2013-06-25 2020-10-23 佛恩多制药有限公司 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
CN105518017B (zh) * 2013-06-25 2020-07-14 佛恩多制药有限公司 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
US10413557B2 (en) 2014-12-23 2019-09-17 Forendo Pharma Ltd. Prodrugs of 17.BETA.-HSD1-inhibitors
EP3237430B1 (en) 2014-12-23 2019-03-20 Forendo Pharma Ltd PRODRUGS OF 17ß -HSD1 -INHIBITORS

Also Published As

Publication number Publication date
IL271218A (en) 2020-01-30
IL294140A (en) 2022-08-01
KR20200023362A (ko) 2020-03-04
JP2020522539A (ja) 2020-07-30
MX2022000747A (es) 2023-01-24
WO2018224736A2 (en) 2018-12-13
JP2024028916A (ja) 2024-03-05
AU2018279205B2 (en) 2021-04-15
US10717761B2 (en) 2020-07-21
WO2018224736A3 (en) 2019-01-17
CN110945007A (zh) 2020-03-31
JP7401576B2 (ja) 2023-12-19
SG11201911776PA (en) 2020-01-30
MX2019014677A (es) 2022-04-01
US20220127303A1 (en) 2022-04-28
CL2019003562A1 (es) 2020-06-12
KR102420512B1 (ko) 2022-07-13
EP3634975B1 (en) 2024-02-28
CN110945007B (zh) 2022-11-18
JP2022065030A (ja) 2022-04-26
IL294140B1 (en) 2024-05-01
JP7064515B2 (ja) 2022-05-10
CA3066196A1 (en) 2018-12-13
BR112019025782A2 (pt) 2020-06-23
ZA201908404B (en) 2023-11-29
AU2018279205A1 (en) 2020-01-16
DK3634975T3 (da) 2024-05-27
EP3634975A2 (en) 2020-04-15
CA3066196C (en) 2023-08-29
UA126342C2 (uk) 2022-09-21
FI3634975T3 (fi) 2024-05-03
CN115716860A (zh) 2023-02-28
NZ760155A (en) 2022-09-30
PT3634975T (pt) 2024-05-20
US20180354984A1 (en) 2018-12-13
US20200317718A1 (en) 2020-10-08
US11254703B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
BR112017016766A2 (pt) composições farmacêuticas para terapia de combinação
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
NZ754764A (en) Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses
MX2020011873A (es) Nuevos derivados de quinolina.
PH12021551232A1 (en) Haloallylamine compounds and application thereof
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
EA202191531A1 (ru) Терапевтически активные стероидные производные
MX2023011057A (es) Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2).
CR20230192A (es) Formulación sólida
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
MX2018008443A (es) Composición farmacéutica que comprende nebivolol con tasa de disolución mejorada.
MX2021000475A (es) Isoxazol como agonista del receptor fxr.
JOP20200233A1 (ar) مثبطات إفراز بروتين أساسه تراي أزا سيكلو دوديكان سلفوناميد ('tcd')